Tailored radiation blasts lung tumors faster in new trial

NCT ID NCT06080061

Recruiting now Disease control Sponsor: Stanford University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 1 trial tests a personalized, accelerated radiation therapy for locally advanced lung cancer. The radiation dose is tailored to each patient's tumor size and location, aiming to deliver a higher dose in fewer sessions. The study will enroll 45 adults with non-small cell or small cell lung cancer who are also receiving chemotherapy. The main goal is to check for serious lung and esophagus side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: hypofractionated accelerated radiation therapy
What this could lead to: If successful, this could lead to a more effective and personalized radiation treatment for lung cancer, potentially improving tumor control while reducing side effects.
What could go wrong: This is an early phase 1 trial with only 45 participants, so safety and effectiveness are not yet proven. There is a risk of lung, esophageal, or heart side effects from the higher radiation dose.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER

Contacts and locations

Locations

Stanford Cancer Center South Bay
RECRUITING

San Jose, California, 95124, United States
Stanford University
RECRUITING

Palo Alto, California, 94305, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.